155 related articles for article (PubMed ID: 6191561)
1. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
[TBL] [Abstract][Full Text] [Related]
2. Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group.
Kahn SB; Spiers A; Knospe WH; Soojian M; Glick JH
Am J Clin Oncol; 1987 Feb; 10(1):78-81. PubMed ID: 2435142
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.
Arlin ZA; Flomenberg N; Gee TS; Kempin SJ; Dellaquila C; Mertelsmann R; Straus DJ; Young CW; Clarkson BD
Cancer Clin Trials; 1981; 4(3):317-21. PubMed ID: 6895190
[TBL] [Abstract][Full Text] [Related]
4. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Hines JD; Oken MM; Mazza JJ; Keller AM; Streeter RR; Glick JH
J Clin Oncol; 1984 Jun; 2(6):545-9. PubMed ID: 6233399
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Jehn U; Heinemann V
Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).
Fanucchi MP; Arlin ZA
Cancer Chemother Pharmacol; 1982 Dec; 10(1):27-8. PubMed ID: 6961970
[TBL] [Abstract][Full Text] [Related]
7. High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
Cassileth PA; Lyman GH; Bennett JM; Glick JH; Oken MM
Am J Clin Oncol; 1984 Aug; 7(4):361-3. PubMed ID: 6547566
[TBL] [Abstract][Full Text] [Related]
8. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
Legha SS; Keating MJ; Zander AR; McCredie KB; Bodey GP; Freireich EJ
Ann Intern Med; 1980 Jul; 93(1):17-21. PubMed ID: 6930826
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study.
Krischer J; Land VJ; Civin CI; Ragab AH; Mahoney DH; Frankel LS
Cancer; 1984 Jul; 54(2):207-10. PubMed ID: 6586277
[TBL] [Abstract][Full Text] [Related]
10. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
Naparstek E; Shinar E; Polliack A
Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
[TBL] [Abstract][Full Text] [Related]
11. Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Arlin ZA; Sklaroff RB; Gee TS; Kempin SJ; Howard J; Clarkson BD; Young CW
Cancer Res; 1980 Sep; 40(9):3304-6. PubMed ID: 6933002
[TBL] [Abstract][Full Text] [Related]
12. Treatment of refractory adult lymphoblastic leukemia (ALL) with 4'(9-acridinylamino) methanesulfon-M-anisidide (AMSA).
Arlin ZA; Fanucchi MP; Gee TS; Kempin SJ; Mertelsmann R; Young CW; Clarkson BD
Blood; 1982 Nov; 60(5):1224-6. PubMed ID: 6957250
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
[TBL] [Abstract][Full Text] [Related]
14. New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA.
Jehn U; Heinemann V
Anticancer Res; 1991; 11(2):705-11. PubMed ID: 2064323
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinoma.
Dombernowsky P; Siegenthaler P; Somers R; Hansen HH
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):71-4. PubMed ID: 6896306
[TBL] [Abstract][Full Text] [Related]
16. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II study of m-AMSA administered as a continuous infusion.
Micetich KC; Zwelling LA; Gormley P; Young RC
Cancer Treat Rep; 1982 Oct; 66(10):1813-7. PubMed ID: 6897013
[TBL] [Abstract][Full Text] [Related]
18. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
[TBL] [Abstract][Full Text] [Related]
20. m-AMSA: phase II trial in advanced lymphoma and leukemia.
Case DC
Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
